Does using pembrolizumab alone work well for Non-Small Cell Lung Cancer with high PD-L1 levels?
For people with advanced non-small cell lung cancer (NSCLC) that has high levels of PD-L1 (a protein that helps cancer hide from the immune system), pembrolizumab alone is a well-established treatment option. PD-L1 levels of 50% or higher on tumor cells predict a stronger response to immunotherapy. Real-world studies confirm that pembrolizumab monotherapy provides meaningful long-term outcomes for many patients in this group.
What the research says
A large real-world meta-analysis of over 17,500 patients with advanced NSCLC and PD-L1 ≥50% found that first-line pembrolizumab alone led to a mean overall survival of 21 months and a 5-year survival rate of 29% 5. Progression-free survival averaged 8.7 months, and serious side effects (grade 3 or higher) occurred in about 12% of patients 5. These results support pembrolizumab monotherapy as a standard first-line option for this population. However, the same analysis noted that older age (70 years or older) and poorer performance status were linked to worse outcomes 5. A phase 2 trial also showed that adding stereotactic body radiotherapy to pembrolizumab did not significantly improve response rates compared to pembrolizumab alone in advanced NSCLC, regardless of PD-L1 level 9. Ongoing research is exploring combinations to improve upon pembrolizumab alone. For example, the TROPION-Lung08 phase 3 trial is testing whether adding the antibody-drug conjugate datopotamab deruxtecan to pembrolizumab improves outcomes in PD-L1-high advanced NSCLC 10. Another study found that for patients with poor performance status, adding low-dose chemotherapy to pembrolizumab did not improve response rates compared to pembrolizumab alone 11. These findings suggest that for most patients with high PD-L1, pembrolizumab alone remains a strong choice, though individual factors like age and overall health matter.
What to ask your doctor
- Based on my PD-L1 level and overall health, is pembrolizumab alone the best first treatment for me?
- What are the chances of long-term survival with pembrolizumab alone, and what side effects should I watch for?
- Would adding chemotherapy or radiation to pembrolizumab offer any benefit for my specific situation?
- How will my age and performance status affect how well pembrolizumab might work for me?
- Are there any newer combination treatments I should consider, and are they available through clinical trials?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.